BDNF and Cognitive Function in Chilean Schizophrenic Patients.

BDNF plasma levels Montreal Cognitive Assessment (MoCA) brain-derived neurotrophic factor cognition cognition biomarker cognitive impairment neurotrophins schizophrenia

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
24 Jun 2023
Historique:
received: 21 04 2023
revised: 16 06 2023
accepted: 19 06 2023
medline: 17 7 2023
pubmed: 14 7 2023
entrez: 14 7 2023
Statut: epublish

Résumé

Despite cognitive symptoms being very important in schizophrenia, not every schizophrenic patient has a significant cognitive deficit. The molecular mechanisms underlying the different degrees of cognitive functioning in schizophrenic patients are not sufficiently understood. We studied the relation between brain-derived neurotrophic factor (BDNF) and cognitive functioning in two groups of schizophrenic patients with different cognitive statuses. According to the Montreal Cognitive Assessment (MoCA) results, the schizophrenic patients were classified into two subgroups: normal cognition (26 or more) and cognitive deficit (25 or less). We measured their plasma BDNF levels using ELISAs. The statistical analyses were performed using Spearman's Rho and Kruskal-Wallis tests. We found a statistically significant positive correlation between the plasma BDNF levels and MoCA score (

Identifiants

pubmed: 37445746
pii: ijms241310569
doi: 10.3390/ijms241310569
pmc: PMC10341589
pii:
doi:

Substances chimiques

Brain-Derived Neurotrophic Factor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agencia Nacional de Investigación y Desarrollo
ID : 11231216
Organisme : Ministry of Economy, Development and Tourism
ID : P09-015-F

Références

Lancet. 2016 Jul 2;388(10039):86-97
pubmed: 26777917
Neuron. 2006 Oct 5;52(1):139-53
pubmed: 17015232
Psychol Med. 2022 Aug;52(11):2177-2188
pubmed: 34158132
J Neurosci Methods. 2010 Mar 15;187(1):73-7
pubmed: 20043947
Am J Psychiatry. 1996 Mar;153(3):321-30
pubmed: 8610818
Schizophr Res. 2007 Aug;94(1-3):1-11
pubmed: 17524622
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Eur Neuropsychopharmacol. 2005 May;15(3):319-29
pubmed: 15820422
Schizophr Res. 2004 Dec 15;72(1):1-3
pubmed: 15531401
Nat Rev Neurosci. 2003 Apr;4(4):299-309
pubmed: 12671646
Eur Psychiatry. 2004 Sep;19(6):326-37
pubmed: 15363470
Front Psychiatry. 2013 Jun 17;4:45
pubmed: 23785335
Mol Psychiatry. 2011 Sep;16(9):960-72
pubmed: 20733577
BMC Psychiatry. 2013 Jan 15;13:27
pubmed: 23320462
Int J Neuropsychopharmacol. 2010 May;13(4):535-9
pubmed: 19941699
J Psychiatr Res. 2013 Oct;47(10):1376-82
pubmed: 23806580
Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12547-52
pubmed: 8901619
Psychiatry Res. 2015 Mar 30;226(1):1-13
pubmed: 25681004
Neuropsychobiology. 2021;80(5):411-424
pubmed: 33706323
Nat Rev Neurosci. 2005 Aug;6(8):603-14
pubmed: 16062169
Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15788-92
pubmed: 15505222
Schizophr Res Cogn. 2015 Dec 17;2(4):172-178
pubmed: 29114461
Asian J Psychiatr. 2022 Apr;70:103029
pubmed: 35189473
Psychopharmacology (Berl). 2012 Jul;222(2):277-84
pubmed: 22274000
Neuropharmacology. 1998 Dec;37(12):1553-61
pubmed: 9886678
J Abnorm Psychol. 2018 Feb;127(2):216-227
pubmed: 29528675
Schizophr Res. 2013 Oct;150(1):42-50
pubmed: 23911259
Nat Rev Neurosci. 2001 Jan;2(1):24-32
pubmed: 11253356
Front Psychiatry. 2021 Jun 16;12:662407
pubmed: 34220575
Nat Rev Dis Primers. 2015 Nov 12;1:15067
pubmed: 27189524
Psychol Med. 2019 Sep;49(12):1971-1979
pubmed: 31284882
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1836-40
pubmed: 21930178
Dialogues Clin Neurosci. 2019 Sep;21(3):239-248
pubmed: 31749648
Nat Rev Neurosci. 2009 Feb;10(2):126-40
pubmed: 19153576
Nat Rev Neurosci. 2002 Dec;3(12):965-74
pubmed: 12461553
J Affect Disord. 2021 Feb 15;281:264-270
pubmed: 33341008
J Psychiatr Res. 2012 Jan;46(1):1-11
pubmed: 22030467
Schizophr Res. 2011 Jul;129(2-3):201-4
pubmed: 21470828
Psychiatr Genet. 2019 Oct;29(5):200-210
pubmed: 31465000
Neuroscience. 2003;121(2):341-54
pubmed: 14521993

Auteurs

Rodrigo R Nieto (RR)

Clínica Psiquiátrica Universitaria, Hospital Clínico de la Universidad de Chile, Universidad de Chile, Santiago 8380453, Chile.
Departamento de Psiquiatría y Salud Mental Norte, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.
Departamento de Neurociencias, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.
Laboratorio de Neurobiología Celular y Molecular, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.

Hernán Silva (H)

Clínica Psiquiátrica Universitaria, Hospital Clínico de la Universidad de Chile, Universidad de Chile, Santiago 8380453, Chile.
Departamento de Psiquiatría y Salud Mental Norte, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.

Alejandra Armijo (A)

Hospital Dr. José Horwitz Barak, Servicio de Salud Metropolitano Norte, Santiago 8431621, Chile.

Rubén Nachar (R)

Hospital Dr. José Horwitz Barak, Servicio de Salud Metropolitano Norte, Santiago 8431621, Chile.

Alfonso González (A)

Hospital Dr. José Horwitz Barak, Servicio de Salud Metropolitano Norte, Santiago 8431621, Chile.
Escuela de Medicina, Universidad Finis Terrae, Santiago 7501015, Chile.

Carmen Paz Castañeda (CP)

Hospital Dr. José Horwitz Barak, Servicio de Salud Metropolitano Norte, Santiago 8431621, Chile.

Cristián Montes (C)

Clínica Psiquiátrica Universitaria, Hospital Clínico de la Universidad de Chile, Universidad de Chile, Santiago 8380453, Chile.
Departamento de Psiquiatría y Salud Mental Norte, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.

Manuel Kukuljan (M)

Departamento de Neurociencias, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.
Laboratorio de Neurobiología Celular y Molecular, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH